This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| A. Classification codes | C60 (C60.0 prepuce, C60.1 glans penis, C60.2 body of penis, C60.8 overlapping sites, C60.9 penis, unspecified) |
| B. Synonyms | Penile squamous cell carcinoma, penile cancer, Glans carcinoma, penile intraepithelial neoplasia (PeIN) |
| C. Adult onset | Very high — occurs mainly at age 60 and over. Relatively rare in Asia including Korea (74 cases in Korea in 2015), while in some regions of developing countries it accounts for 10–20% of cancers in men. |
| Special Copayment Reduction: V193 | 5 years from the date of cancer patient registration | copayment 5% | |
Penile cancer is an ancient disease recorded for thousands of years. Descriptions of penile lesions remain in the medical literature of ancient Egypt and India, and the fact that circumcision has long been performed to prevent penile disease historically suggests a link between penile cancer and hygiene. Clinical research on penile cancer in the modern sense began in earnest with the development of surgery in the 19th century. In 1887, Horowitz described the standard technique of penectomy, and in the early 20th century the concept of inguinal lymph node dissection (ILND) became established.
The association between HPV (human papillomavirus) and penile cancer began to be elucidated in the 1970s–80s, centered on the group of Harald zur Hausen, and HPV-16 and HPV-18 were subsequently identified as the main oncogenic viruses of penile cancer. zur Hausen received the 2008 Nobel Prize in Physiology or Medicine for this work. The introduction of the HPV concept into penile cancer research was a spillover effect from cervical cancer research.
In Korea, penile cancer is a rare malignancy, with fewer than 100 registered cases nationwide per year. In Korea, clinical practice guidelines for penile cancer have been developed and maintained mainly by the Korean Urological Association and the Korean Urological Oncology Society, and Korean guidelines based on the EAU (European Association of Urology) guidelines are applied. Recently, expansion of HPV vaccination, education on prevention of sexually transmitted infections, and improvement of male hygiene practices have been treated as important for penile cancer prevention.
The most important risk factors for penile cancer are HPV infection, phimosis and poor hygiene. Worldwide, about 40–50% of penile cancers are HPV-related, and the HPV prevalence among Korean penile cancer patients has been reported at about 36%. The most common type is HPV-16 (70–80%), followed by HPV-18. HPV infection is the starting point of the HPV-associated pathway, which progresses through penile intraepithelial neoplasia (PeIN) to invasive carcinoma.
Phimosis is a very strong risk factor that increases the risk of penile cancer 11.4-fold (invasive) to 3.8-fold (carcinoma in situ). With phimosis, secretions (smegma) accumulate around the glans, causing chronic irritation and inflammation and promoting the retention and penetration of viruses such as HPV. Circumcision in the neonatal period or early childhood reduces the risk of penile cancer more than 3-fold.
Other risk factors include smoking (an independent risk factor, increasing penile cancer risk 4.5-fold), multiple sexual partners, sexually transmitted infections (especially HSV-2), Bowenoid papulosis, lichen sclerosus, phototherapy (PUVA), and immunosuppressed states (HIV infection, after organ transplantation). Incidence is particularly high among older people, people with low income, and residents of developing countries.
Penile cancer is divided into HPV-associated and HPV-independent pathways, each with characteristic molecular abnormalities. In HPV-associated penile cancer, the key carcinogenic mechanisms are suppression of p53 function by the HPV E6 protein and suppression of pRb function by the E7 protein. In these tumors p16INK4a is overexpressed (release of p16 repression through pRb binding by E7), and p16INK4a immunohistochemical positivity is used as a surrogate marker of HPV infection.
In HPV-independent penile cancer, TP53 mutations are very common (>80%), and CDKN2A loss (p16), HRAS mutations, EGFR overexpression and PIK3CA mutations are observed. FGFR3 mutations have also been reported in some tumors. Comprehensive genomic profiling (NGS) is used to identify TMB-H (high tumor mutational burden) and MSI-H tumors and to assess eligibility for immune checkpoint inhibitors.
PD-L1 expression has been identified in penile cancer, and the potential response of high-expressing tumors to immune checkpoint inhibitors such as pembrolizumab is being studied. ERBB2 (HER2) amplification and MET amplification have also been reported in some cases. Pharmacogenomically, response to platinum-based chemotherapy may be related to TP53 mutation status. Overall, penile cancer shows a relatively low somatic mutational burden, but the immune tissue environment is more active in HPV-associated tumors.
Penile cancer is a relatively rare malignancy, accounting for 0.5–2% of cancers in men worldwide. In 2020, about 36,068 new cases were diagnosed worldwide. Incidence varies greatly by region: it is high in South America (Brazil, Paraguay), Africa and parts of Asia (4–5 cases per 100,000 men) and low in North America and Northern Europe (0.5–1 case). Incidence is very low in Jewish and Muslim communities where circumcision is customary.
In Korea, 74 cases were reported in 2015, a rare cancer accounting for only 0.03% of all malignancies. The main age of onset is 60 and over, and the proportion of HPV-associated penile cancer in Asian populations is similar to that in Western countries. In a study of Korean penile cancer patients, the HPV positivity rate was 36% and the p16INK4a overexpression rate was 48%. There is an epidemiologic observation that changes in male circumcision rates may affect penile cancer incidence in the long term.
Worldwide, regions where penile cancer incidence is declining owing to improved economic and hygiene standards in developing countries and expanded HPV vaccination coexist with regions where it is increasing because of population aging. Occupational characteristics (socioeconomically vulnerable groups), smoking and having had multiple sexual partners contribute to differences in incidence between groups.
Penile cancer develops through two main pathways. The first is the HPV-associated pathway, progressing in the order HPV-16/18 infection → penile intraepithelial neoplasia (PeIN, differentiated or basaloid/warty type) → invasive carcinoma. The HPV E6 protein degrades the p53 protein via the ubiquitin–proteasome pathway, suppressing the DNA damage response, and the E7 protein binds the pRb protein and activates the E2F transcription factor, abnormally driving the cell cycle.
The second is the HPV-independent pathway, in which epithelial damage and dysplasia occur persistently due to phimosis, chronic inflammation (lichen sclerosus, lichen planus, etc.) and chemical irritation (smegma), progressing to invasive carcinoma through TP53 mutation and p16/CDKN2A loss. In this pathway, differentiated PeIN is the precursor lesion.
In both pathways, hyperactivation of EGFR signaling and activation of the PI3K/AKT/mTOR pathway promote tumor proliferation and survival. Lymph node metastasis proceeds through the rich lymphatic system of the penis in the order inguinal → pelvic lymph nodes, and the status of the inguinal lymph nodes, the initial site of metastasis, is the most important staging and prognostic factor. Distant metastasis occurs in the lungs, liver and bone, in that order.
The most common early symptom of penile cancer is an ulcer, nodule or wart-like lesion of the penis, or a penile lesion that persistently fails to heal. It occurs mainly on the glans or prepuce, and because it is initially painless, patients often delay seeking medical care. As the lesion progresses, discharge, foul odor, bleeding and pain may occur.
In patients with phimosis, the lesion is hidden beneath the prepuce, delaying diagnosis further. When inguinal lymph node metastasis occurs, it may present as a painless or tender mass in the groin, and as it progresses it presents as an ulcerated inguinal mass with skin involvement. With distant metastasis, systemic symptoms such as cough, bone pain, abdominal pain and weight loss may appear. Because patients tend to feel ashamed of or ignore penile lesions, delaying diagnosis by several months or more, active physical examination by clinicians and patient education are important.
On physical examination, a hard, irregular ulcerative lesion, or a papillary or hyperkeratotic nodule is observed on the penis. The glans, prepuce and frenulum are the most common sites. Lesions may be single or multiple. Retracting the prepuce and examining the entire penis is basic, and when phimosis is present, circumcision may be needed to identify the lesion.
If indurated lymph nodes are palpated in the groin, metastasis should be suspected. However, it is important to distinguish reactive lymphadenopathy due to infection from metastatic lymph nodes, and reassessment 4–6 weeks after antibiotic treatment is recommended. A positive p16INK4a immunohistochemistry result suggests an HPV-associated tumor and is used for prognostic prediction. On histology, squamous cell carcinoma (SCC) is the most common histologic type and is subdivided into subtypes such as warty, basaloid and mixed.
There is currently no standardized population screening program for penile cancer. HPV vaccination is the most effective means of primary prevention of penile cancer and is in effect the most powerful population prevention tool. HPV vaccination of males is currently being expanded in Korea.
For screening of high-risk groups, regular penile self-examination and regular dermatology and urology checkups are recommended for men with risk factors such as lichen sclerosus, phimosis and recurrent sexually transmitted infections. Penile lesions that persistently fail to heal, painless ulcers or growing nodules require immediate medical evaluation. Patients already diagnosed with penile intraepithelial neoplasia (PeIN) lesions should undergo regular follow-up to detect progression to invasive carcinoma early.
Definitive diagnosis is made by tissue biopsy of the penile lesion. Needle biopsy or punch biopsy is generally used, and for preputial lesions circumcision (posthectomy) itself can serve as a diagnostic excision. Pathologic examination determines the histologic type (squamous cell carcinoma, warty carcinoma, basaloid carcinoma, etc.), degree of differentiation and HPV association (p16 immunostaining).
For staging, penile MRI (optimal for assessing corporal invasion), pelvic and abdominal CT (lymph node and distant metastasis), and inguinal ultrasound and fine-needle aspiration cytology (FNA) (when lymph node metastasis is suspected) are performed. Positron emission tomography (PET-CT) is used as an adjunct for evaluating lymph node and distant metastasis. Staging follows the AJCC (American Joint Committee on Cancer) or UICC TNM classification. The presence or absence of lymph node metastasis is the most critical factor in determining stage and treatment strategy.
When inguinal lymph node biopsy is needed, dynamic sentinel lymph node biopsy (DSLNB) is an effective method for detecting micrometastases in a clinically negative groin. For molecular diagnosis, HPV DNA testing, p16 immunostaining and TP53 mutation analysis are used for prognostic prediction and identification of therapeutic targets.
Treatment of penile cancer is determined by stage, lesion location and size, and whether the patient wishes to preserve the penis. For early lesions (T1–T2, superficial), penile-sparing treatment is recommended. Laser therapy (CO₂ or Nd:YAG), Mohs micrographic surgery, radiotherapy (external beam or brachytherapy), local excision and glansectomy are performed with the aim of preserving penile function.
For locally advanced lesions (T3–T4) or large tumors, partial penectomy or total penectomy may be needed. When inguinal lymph node metastasis is confirmed, inguinal lymph node dissection (ILND) is performed. In a clinically negative groin, sentinel lymph node biopsy or modified ILND is performed to identify micrometastases. With pelvic lymph node metastasis, pelvic lymph node dissection is additionally performed.
In metastatic or unresectable penile cancer, chemotherapy is central, and platinum-based combination regimens such as TIP (paclitaxel, ifosfamide, cisplatin) and BMP (bleomycin, MTX, cisplatin) are used. Immune checkpoint inhibitors (pembrolizumab) have been reported to be effective in MSI-H/TMB-H or PD-L1-high penile cancer, and their indications are expanding. Neoadjuvant chemotherapy is used before surgery to shrink the tumor when there are multiple inguinal lymph node metastases.
The prognosis of penile cancer is determined by stage, particularly by the presence or absence of inguinal lymph node metastasis.
| Stage | 5-year survival rate (approximate) |
|---|---|
| T1 (invasion of lamina propria) | 85–90% |
| T2 (corporal invasion) | 70–85% |
| T3 (urethral invasion) | 50–60% |
| No lymph node metastasis (N0) | 85–100% |
| Inguinal lymph node metastasis (N1–N2) | 40–60% |
| Pelvic lymph node metastasis (N3) | <20% |
HPV-associated penile cancer tends to have a relatively better prognosis than HPV-independent penile cancer. Diagnostic delay (6 months or more) markedly worsens the prognosis. Optimal management of the inguinal lymph nodes (appropriate ILND) is key to improving long-term survival. Because salvage therapy is of limited effectiveness at recurrence, optimal initial treatment is very important.
The most effective way to prevent penile cancer is HPV vaccination. The 9-valent HPV vaccine (Gardasil 9) protects against HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58, and vaccination is also recommended for males. The protective effect is greater the earlier vaccination begins before sexual debut (before ages 9–14), but catch-up vaccination up to age 26 is also recommended for unvaccinated adults. The effect of the HPV vaccine in preventing penile cancer in men is estimated to be comparable to its effect in cervical cancer.
Circumcision in the neonatal period or childhood is known to reduce the risk of penile cancer more than 3-fold. Circumcision in adults may also have some preventive effect. Penile hygiene education, especially promoting the importance of keeping the area under the prepuce clean, is a practical prevention strategy alongside HPV vaccination. Smoking cessation contributes independently to reducing penile cancer risk. Early treatment of precursor conditions such as lichen sclerosus and recurrent sexually transmitted infections, and regular follow-up of penile intraepithelial neoplasia (PeIN) lesions, are also important for preventing invasive carcinoma.